Cover Image
市場調查報告書

Botox(偏頭痛)- 預測與市場分析

Botox (Migraine) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 301153
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
Botox(偏頭痛)- 預測與市場分析 Botox (Migraine) - Forecast and Market Analysis to 2023
出版日期: 2014年03月31日 內容資訊: 英文 42 Pages
簡介

偏頭痛的治療藥市場上的學名藥已呈飽和狀態,上市剩下來的品牌藥,除了慢性偏頭痛治療藥Botox之外,預測在今後數年將失去壟斷性。偏頭痛的治療藥市場預測到2023年將擴大到37億美金的規模,並以CAGR3.6%的速度成長。

本報告提供偏頭痛治療藥──Botox之調查分析,提供疾病概要和治療指南,競爭情形,產品資訊,銷售額預測等,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
    • 預測
  • 症狀
    • 徵兆
    • 前驅症狀
    • 頭痛
    • 後發症狀

第4章 疾病的管理

  • 治療概要
    • 急性偏頭痛
    • 預防性偏頭痛

第5章 競爭評估

  • 概要
  • 策略性競爭企業的評估

第6章 Botox(onabotulinum toxin A)

  • 概要
  • 功效
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄

圖表

目錄
Product Code: GDHC378DFR

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

Onabotulinum toxins are produced by the bacterium Clostridium botulinum, which was first isolated in 1895. They are potent inhibitors of neurotransmission between neurons themselves and also to muscle. Out of the seven subtypes of onabotulinum toxin (A-G), onabotulinum neurotoxin type A is the most commonly used and thoroughly investigated subtype. Onabotulinum toxin type A is currently marketed as Botox by Allergan. In recent years, Botox has gained a great deal of attention and has gained FDA (2010) as well as MHRA (2013) approval as treatment for chronic migraine.

Scope

  • Overview of Migraine, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Botox including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Botox for the top five countries from 2012 to 2023.
  • Sales information covered for the US, Germany, Italy, Spain and the UK.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Migraine
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Botox performance
  • Obtain sales forecast for Botox from 2012-2023 in the top five countries (the US, Germany, Italy, Spain and the UK)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
  • 3.2. Symptoms
    • 3.2.1. Premonitory Phase
    • 3.2.2. Aura Phase
    • 3.2.3. Headache Phase
    • 3.2.4. Postdrome Phase

4. Disease Management

  • 4.1. Treatment Overview
    • 4.1.1. Acute Migraine Treatment
    • 4.1.2. Preventive Migraine Treatment

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Botox (onabotulinum toxin A)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed Migraine Patients
    • 7.4.2. Percent Drug-treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in this Study
  • 7.6. Survey of Prescribing Physicians
  • 7.7. About the Authors
    • 7.7.1. Author
    • 7.7.2. Reviewer
    • 7.7.3. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Disclaimer

List of Tables

  • Table 1: Classification of Migraine Subtypes
  • Table 2: Diagnostic Criteria for Migraine with Aura
  • Table 3: Diagnostic Criteria for Migraine without Aura
  • Table 4: Treatment Guidelines for Migraine
  • Table 5: Most Prescribed Drugs for Migraine by Class in the Major Markets, 2013
  • Table 6: Product Profile - Botox
  • Table 7: Botox SWOT Analysis, 2013
  • Table 8: Global Sales Forecasts ($m) for Botox, 2012-2023
  • Table 9: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Migraine Treatment Algorithm in the 7MM
Back to Top